ESR1 and breast cancer: Use of the core biopsy is foundational to treatment planning, to identify patients with early‐stage ER+ HER2− breast cancer and low‐intermediate grade tumors, lobular histology, or low‐risk genomic assays results for whom neoadjuvant endocrine treatment can be administered when surgery is deferred.1, 2, 3, 4